1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy
- Contribution to journal › Article
- 2024
-
Mark
Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics
- Contribution to journal › Article
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
- 2023
-
Mark
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
- Contribution to journal › Article
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
- Contribution to journal › Article
